| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 28 Mar 2025 | 28 Mar 2025 |
| Outcome of Board Meeting | ||
| Board Meeting | 1 Mar 2025 | 1 Mar 2025 |
| Outcome of Board Meeting - Sale of property | ||
| Board Meeting | 6 Feb 2025 | 14 Jan 2025 |
| UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2025 inter alia to consider and approve unaudited financial results (standalone and consolidated) for the quarter and nine months ended December 31 2024. Unaudited Financial Results (Consolidated & Standalone) for the quarter and nine-months ended 31st December 2024 Included Mr. Uttkarsh Patil, Chief Manufacturing officer - Formulations, as a senior Management Personnel under SEBI LODR Regulations with effect from 6th February 2025 (As Per BSE Announcement dated on 06.02.2025) | ||
| Board Meeting | 13 Nov 2024 | 25 Oct 2024 |
| UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Unaudited Financial Results for the quarter ended September 30 2024. Unaudited Financial Statements (Consolidated & Standalone) for the second quarter and half year ended 30th September 2024 (As Per BSE Announcement Dated on: 13/11/2024) | ||
| Board Meeting | 30 Sep 2024 | 23 Sep 2024 |
| UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/09/2024 inter alia to consider and approve integration and consolidation of the generics formulations business in the US market. Purchase of Product approvals and all goodwill associated with Nine (9) ANDAs owned by Bayshore Pharmaceuticals LLC, USA for USD 2,650,000 by the Company and Purchase of USA generics formulations business as a going concern through slump sale ./ transfer of business by Unichem Pharmaceuticals (USA) Inc through assets purchase agreements for USD 10,000,000. (As per BSE Announcement dated on 30/09/2024) Board approved entering into following agreements with Bayshore Pharmaceuticals LLC, USA (Bayshore USA) (wholly owned step-down subsidiary of Ipca Laboratories Limited, Companys holding company) for: a. Purchase all of rights, title and interest in the Product approvals and all goodwill associated with Nine (9) ANDAs owned by Bayshore USA for US dollars two million six hundred fifty thousand ($ 2,650,000) through asset purchase agreement subject to required consents and approvals, if any; and b. Unichem Pharmaceuticals (USA) Inc (Unichem USA), a wholly owned subsidiary of the Company, to purchase USA generics formulations marketing/distribution business of Bayshore USA (Step-down subsidiary of parent company Ipca Laboratories Ltd) as a going concern through slump sale/transfer of entire business (debt free) and all goodwill associated with the business through asset purchase agreement for US dollars ten million ($10,000,000) (As Per BSE Bulletin Dated on 04.10.2024) | ||
| Board Meeting | 8 Aug 2024 | 26 Jul 2024 |
| UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve Unaudited financial results (standalone & consolidated) for the quarter ended 30th June 2024. PFA herewith Outcome of Board Meeting (As Per BSE Announcement Dated on 08.08.2024) | ||
| Board Meeting | 22 May 2024 | 9 May 2024 |
| UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 inter alia to consider and approve Financial results for quarter and year ended March 31 2024 Outcome of Board Meeting PFA herewith financial results for the quarter and year ended 31st March 2024 (As Per BSE Announcement dated on 22.05.2024) | ||
Revenue increased by 14.5% to ₹533 crore from ₹466 crore the previous year.
Bayshore Pharmaceuticals is a 100% subsidiary of Unichem Laboratories' parent firm, Ipca Laboratories Ltd.
According to the corporation, the observations have no influence on business continuity or supplies to the US market.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Birla Estates, Lupin, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
